Venu Alapati
Psychiatry · Indianapolis, INNPI 1104239516
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 405 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$695
- Supernus Pharmaceuticals, Inc.$575
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$484
- Neurocrine Biosciences, Inc.$483
- plus $3K from 19 others
What the payments were for
- Food & beverage$7,05398%
- Education$1182%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 44 | $1,269 |
| AbbVie(2 entities) | 76 | $1,109 |
| Alkermes, Inc. | 32 | $695 |
| Supernus Pharmaceuticals, Inc. | 37 | $575 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 31 | $484 |
| Neurocrine Biosciences, Inc. | 29 | $483 |
| Teva Pharmaceuticals USA, Inc. | 21 | $410 |
| Corium, LLC | 21 | $318 |
| Johnson & Johnson | 20 | $296 |
| Otsuka America Pharmaceutical, Inc. | 14 | $267 |
| E.r. Squibb & Sons, L.L.C. | 12 | $210 |
| Lundbeck LLC | 11 | $199 |
| Tris Pharma Inc | 19 | $194 |
| Indivior Inc. | 10 | $160 |
| Ironshore Pharmaceuticals Inc. | 7 | $111 |
| Collegium Pharmaceutical, Inc. | 6 | $95 |
| Rigel Pharmaceuticals, Inc. | 1 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 2 | $31 |
| Vertical Pharmaceuticals, LLC | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Noven Therapeutics, LLC | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,171 in reported general payments places this provider in the 90th percentile of 514 psychiatry providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 36 | $110,488 |
| Paliperidone ErPaliperidone | 16 | $7,738 |
| Divalproex Sodium | 19 | $3,047 |
| Lurasidone Hcl | 12 | $2,182 |
| Trazodone Hcl | 63 | $1,397 |
| Haloperidol | 19 | $1,230 |
| Oxcarbazepine | 13 | $1,025 |
| Lamotrigine | 30 | $540 |
| Quetiapine Fumarate | 15 | $451 |
| Benztropine Mesylate | 28 | $448 |
| Risperidone | 22 | $224 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $174 |
| Sertraline Hcl | 26 | $168 |
| Aripiprazole | 13 | $158 |
| Fluoxetine Hcl | 14 | $41 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $296 | $110,48836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 514 psychiatry providers in Indiana.
Other psychiatry in Indianapolis
- Charles BeasleyIndianapolis$129K
- Dmitry ArbuckIndianapolis$40K
- Albert AllenIndianapolis$24K
- Jerad DaltonIndianapolis$20K
- Alan BreierIndianapolis$19K
- Kristen DaussIndianapolis$16K
- Anantha ShekharIndianapolis$13K
- Maria ValenaIndianapolis$11K
- Robert BakerIndianapolis$11K
- Areef KassamIndianapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.